Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 4/2009

01-03-2009 | Original Article

Inhibition of NF-κB-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2-methyl butyrate

Authors: Guoyi Ma, Nurhayat Tabanca, K. Husnu Can Baser, Nese Kirimer, David S. Pasco, Ikhlas A. Khan, Shabana I. Khan

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2009

Login to get access

Abstract

Purpose

Breast cancer is one of the most prevalent woman cancers. Genomic instability, accumulative mutations, and subsequent changes in intracellular signaling cascades play key roles in the development of human breast cancers. Activation of nuclear factor-κB (NF-κB) has been implicated in oncogenesis of breast cancers and is known to be associated with resistance to anticancer agents and apoptosis. Blocking NF-κB signaling may represent a therapeutic strategy in breast cancer therapy. The objective of this study is to investigate the in vitro effects of epoxypseudoisoeugenol-2-methyl butyrate (EPB), a phenylpropranoid isolated from Pimpinella corymbosa, on the activation of NF-κB, cell growth, cell cycle progression and apoptosis in MCF-7 (estrogen-dependent) and BT-549 (estrogen-independent) breast cancer cells.

Methods

Transcriptional activity of NF-κB was measured by cell based reporter gene assay. Cell proliferation was determined by MTT assay. Cell cycle analysis was carried out by flow cytometry and apoptosis was observed by DAPI staining assy.

Results

EPB inhibited the NF-κB-mediated transcription activity induced by tumor necrosis factor-α (TNF-α) and phorbol myristate acetate (PMA) in MCF-7 cells. EPB also inhibited constitutive NF-κB transcriptional activity in BT-549 cells. EPB inhibited the proliferation of both MCF-7 and BT-549 cells in a concentration- and time-dependent manner. EPB induced cell cycle arrest in G1/G0 phase and apoptosis in both MCF-7 and BT 549 cells.

Conclusions

These in vitro results indicated that EPB has a potential for use against both hormone-dependent and hormone-independent breast cancers and its effects seem to be mediated by inhibiting the NF-κB activity.
Literature
1.
go back to reference Merrill RP, Weed DL (2001) Measuring the public health burden of cancer in the United States through lifetime and age-condition risk estimates. Ann Epidemiol 11:547–553PubMedCrossRef Merrill RP, Weed DL (2001) Measuring the public health burden of cancer in the United States through lifetime and age-condition risk estimates. Ann Epidemiol 11:547–553PubMedCrossRef
2.
go back to reference Perera NM, Gui GP (2003) Multi-ethnic differences in breast cancer: current concepts and future directions. Int J Cancer 106:463–467PubMedCrossRef Perera NM, Gui GP (2003) Multi-ethnic differences in breast cancer: current concepts and future directions. Int J Cancer 106:463–467PubMedCrossRef
3.
go back to reference Cornelissc CJ, Cornelis RS, Devilee P (1996) Gene responsible for familial breast cancer. Pathol Res Practice 192:684–693 Cornelissc CJ, Cornelis RS, Devilee P (1996) Gene responsible for familial breast cancer. Pathol Res Practice 192:684–693
4.
go back to reference Somiari RI, Somiari S, Russell S, Shriver CD (2005) Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci 815:215–225PubMedCrossRef Somiari RI, Somiari S, Russell S, Shriver CD (2005) Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci 815:215–225PubMedCrossRef
5.
go back to reference Walczn FG, Krappmann D, Scheidereit C (1978) The NF-kappa B/Rel and I-kappa B gene families: mediators of immune response and inflammation. J Mol Med 74:749–769CrossRef Walczn FG, Krappmann D, Scheidereit C (1978) The NF-kappa B/Rel and I-kappa B gene families: mediators of immune response and inflammation. J Mol Med 74:749–769CrossRef
6.
go back to reference Baldwin AS (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Ann Rev Immunol 14:649–683CrossRef Baldwin AS (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Ann Rev Immunol 14:649–683CrossRef
7.
go back to reference Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X (2004) Abnormalities in the NF-κB family and related proteins in endometrial carcinoma. J Pathol 204:569–577PubMedCrossRef Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X (2004) Abnormalities in the NF-κB family and related proteins in endometrial carcinoma. J Pathol 204:569–577PubMedCrossRef
8.
go back to reference Wu JT, Kral JG (2005) The NF-κB/IκB signaling system: a molecular target in breast cancer therapy. J Surg Res 123:158–169PubMedCrossRef Wu JT, Kral JG (2005) The NF-κB/IκB signaling system: a molecular target in breast cancer therapy. J Surg Res 123:158–169PubMedCrossRef
9.
go back to reference Biswas DK, Dai S-C, Cruz A, Weiser B, Graner E, Pardee AB (2001) The nuclear factor kappB (NF-κB): a potential therapeutic target for estrogen receptor negative breast cancer. Proc Nat Acad Sci USA 98:10386–10391PubMedCrossRef Biswas DK, Dai S-C, Cruz A, Weiser B, Graner E, Pardee AB (2001) The nuclear factor kappB (NF-κB): a potential therapeutic target for estrogen receptor negative breast cancer. Proc Nat Acad Sci USA 98:10386–10391PubMedCrossRef
10.
go back to reference Cao Y, Karin M (2003) NF-kappa B in mammary gland development and breast cancer. J Mam Gland Biol Neop 8:215–223CrossRef Cao Y, Karin M (2003) NF-kappa B in mammary gland development and breast cancer. J Mam Gland Biol Neop 8:215–223CrossRef
11.
go back to reference Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr (1997) Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639PubMed Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr (1997) Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639PubMed
12.
go back to reference Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE (2004) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100:2952–2956CrossRef Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE (2004) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100:2952–2956CrossRef
13.
go back to reference Jordan VC, Third annual William L (1995) McGuire memorial lecture. “Studies on the estrogen receptor in breast cancer”—20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36:267–286PubMedCrossRef Jordan VC, Third annual William L (1995) McGuire memorial lecture. “Studies on the estrogen receptor in breast cancer”—20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36:267–286PubMedCrossRef
14.
go back to reference Hedden A, Muller V, Jensen EV (1995) A new interpretation of antiestrogen action. Ann NY Acad Sci 761:109–120PubMedCrossRef Hedden A, Muller V, Jensen EV (1995) A new interpretation of antiestrogen action. Ann NY Acad Sci 761:109–120PubMedCrossRef
15.
go back to reference Santos PM, Figueiredo AC, Oliverira MM, Barroso JG, Pedro lG, Deans SG, Tounus AKM, Scheffer JC (1999) Morphological Stability of Pimpinella anisum hairy root cultures and time-course study of their essential oils. Biotech Lett 21:859–864CrossRef Santos PM, Figueiredo AC, Oliverira MM, Barroso JG, Pedro lG, Deans SG, Tounus AKM, Scheffer JC (1999) Morphological Stability of Pimpinella anisum hairy root cultures and time-course study of their essential oils. Biotech Lett 21:859–864CrossRef
16.
go back to reference Bisset NG (2001) (ed) Herbal drugs and phytopharmaceuticals, CRC Press, London, pp 72–75 and pp 375–377 Bisset NG (2001) (ed) Herbal drugs and phytopharmaceuticals, CRC Press, London, pp 72–75 and pp 375–377
17.
go back to reference Tabanca N, Bedir E, Kirimer N, Baser KHC, Khan SI, Jacob MR, Khan IA (2003) Antimicrobial compounds from Pimpinella species growing in Turkey. Planta Medica 69:933–938PubMedCrossRef Tabanca N, Bedir E, Kirimer N, Baser KHC, Khan SI, Jacob MR, Khan IA (2003) Antimicrobial compounds from Pimpinella species growing in Turkey. Planta Medica 69:933–938PubMedCrossRef
18.
go back to reference Tabanca N, Khan SI, Bedir E, Annavarapu S, Willet K, Khan IA, Kirimer N, Baser KHC (2004) Estrogenic activity of isolated compounds and essential oils of Pimpinella species from Turkey, evaluated using a recombinant yeast screen. Planta Medica 70:728–735PubMedCrossRef Tabanca N, Khan SI, Bedir E, Annavarapu S, Willet K, Khan IA, Kirimer N, Baser KHC (2004) Estrogenic activity of isolated compounds and essential oils of Pimpinella species from Turkey, evaluated using a recombinant yeast screen. Planta Medica 70:728–735PubMedCrossRef
19.
go back to reference Tabanca N, Bedir E, Ferraira D, Slade D, Wedge DE, Jacob MR, Khan SI, Khan IA, Kirimer N, Baser KHC (2005) Bioactive constituents from Pimpinella species growing in Turkey. Chemi Biodivers 2:221–232CrossRef Tabanca N, Bedir E, Ferraira D, Slade D, Wedge DE, Jacob MR, Khan SI, Khan IA, Kirimer N, Baser KHC (2005) Bioactive constituents from Pimpinella species growing in Turkey. Chemi Biodivers 2:221–232CrossRef
20.
go back to reference Tabanca N, Ma G, Pasco DS, Bedir E, Kirimer N, Baser KHC, Khan IA, Khan SI (2007) Effect of essential oils and isolated compounds from Pimpinella species on NF-κB: a target for anti-inflammatory therapy. Phytother Res 21:741–745PubMedCrossRef Tabanca N, Ma G, Pasco DS, Bedir E, Kirimer N, Baser KHC, Khan IA, Khan SI (2007) Effect of essential oils and isolated compounds from Pimpinella species on NF-κB: a target for anti-inflammatory therapy. Phytother Res 21:741–745PubMedCrossRef
21.
go back to reference Chang CC, Zhang J, Lombardi L, Neri A, Dalla-Favera R (1994) Mechanism of expression and role in transcriptional control of the proto-oncogene NFKB–2/LYT-10. Oncogene 9:923–933PubMed Chang CC, Zhang J, Lombardi L, Neri A, Dalla-Favera R (1994) Mechanism of expression and role in transcriptional control of the proto-oncogene NFKB–2/LYT-10. Oncogene 9:923–933PubMed
22.
go back to reference Subbaramaiah K, Bulic P, Lin Y, Dannenberg AJ, Pasco DS (2001) Development and use of a gene promoter-based screen to identify novel inhibitors of cyclooxygenase-2 transcription. J Biomol Screening 6:101–110 Subbaramaiah K, Bulic P, Lin Y, Dannenberg AJ, Pasco DS (2001) Development and use of a gene promoter-based screen to identify novel inhibitors of cyclooxygenase-2 transcription. J Biomol Screening 6:101–110
23.
go back to reference Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63PubMedCrossRef Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63PubMedCrossRef
24.
go back to reference Ma G, Mustafa J, Khan SI, Walker LA, Khan IA (2005) Anticancer activity and possible mode of action of 4-O-podophyllotoxin-12-Hydroxyl-octadec-Z-9-enoate. Lipids 40:303–308PubMedCrossRef Ma G, Mustafa J, Khan SI, Walker LA, Khan IA (2005) Anticancer activity and possible mode of action of 4-O-podophyllotoxin-12-Hydroxyl-octadec-Z-9-enoate. Lipids 40:303–308PubMedCrossRef
25.
go back to reference McGuire WL, Chamnese GC, Fuqua SAW (1991) Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571–1577PubMedCrossRef McGuire WL, Chamnese GC, Fuqua SAW (1991) Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571–1577PubMedCrossRef
26.
go back to reference Santen R, Manni A, Harvey H, Redmond C (1990) Endocrine treatment of breast cancer in women. Endocr Rev 11:221–265PubMed Santen R, Manni A, Harvey H, Redmond C (1990) Endocrine treatment of breast cancer in women. Endocr Rev 11:221–265PubMed
27.
go back to reference Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge G Jr (1997) Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639PubMed Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge G Jr (1997) Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639PubMed
28.
go back to reference Bm Rayet, Gelinas C (1999) Aberrant rel/NF-kB genes and activity in human cancer. Oncogene 18:6938–6947CrossRef Bm Rayet, Gelinas C (1999) Aberrant rel/NF-kB genes and activity in human cancer. Oncogene 18:6938–6947CrossRef
29.
go back to reference Bourrs V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V (1994) The NF-κB- and IκB-related proteins in tumor cell lines. Biochem Pharmacol 47:145–149CrossRef Bourrs V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V (1994) The NF-κB- and IκB-related proteins in tumor cell lines. Biochem Pharmacol 47:145–149CrossRef
30.
go back to reference Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M (1999) NF-kappa B function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19:2690–2698PubMed Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M (1999) NF-kappa B function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19:2690–2698PubMed
31.
go back to reference Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG (2001) NF-kappa B and cell cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12:73–90PubMedCrossRef Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG (2001) NF-kappa B and cell cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12:73–90PubMedCrossRef
32.
go back to reference Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999) NF-κB control cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785–5799PubMed Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999) NF-κB control cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785–5799PubMed
33.
go back to reference Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, Benoit V, Merville MP (2000) Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol 60:1085–1089PubMedCrossRef Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, Benoit V, Merville MP (2000) Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol 60:1085–1089PubMedCrossRef
34.
go back to reference Cho MK, Park JW, Jang YP, Kim YC, Kim SG (2002) Potent inhibition of lipopoly-saccharide-inducible nitric oxide synthase expressed by dibenzylbutyroll-actone ligans through inhibition of IκBα phosphorylation and of p65 nuclear translocation in macrophages. Int Immunopharmacol 2:105–116PubMedCrossRef Cho MK, Park JW, Jang YP, Kim YC, Kim SG (2002) Potent inhibition of lipopoly-saccharide-inducible nitric oxide synthase expressed by dibenzylbutyroll-actone ligans through inhibition of IκBα phosphorylation and of p65 nuclear translocation in macrophages. Int Immunopharmacol 2:105–116PubMedCrossRef
Metadata
Title
Inhibition of NF-κB-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2-methyl butyrate
Authors
Guoyi Ma
Nurhayat Tabanca
K. Husnu Can Baser
Nese Kirimer
David S. Pasco
Ikhlas A. Khan
Shabana I. Khan
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0784-9

Other articles of this Issue 4/2009

Cancer Chemotherapy and Pharmacology 4/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine